Metastatic Breast Cancer Treatment Drug: ABRAXANE for Injectable Suspension
For US Residents Only
ABRAXANE for Injectable Suspension
Text size


 

Patient Downloads


Black Box Warning

ABRAXANE is a prescription medicine used to treat breast cancer that has spread to other parts of the body after treatment with certain other medicines has not worked.

ABRAXANE for Injectable Suspension (paclitaxel protein-bound particles for injectable suspension) (albumin bound) is indicated for the treatment of breast cancer after failure of combination chemotherapy for metastatic disease or relapse within 6 months of adjuvant chemotherapy. Prior therapy should have included an anthracycline unless clinically contraindicated.

Living with cancer means living with questions. The resources below can help answer your questions and help you talk about your cancer and its treatment with your doctor.

The items below are for US residents only.

Questions for Your Doctor
A reminder list of important questions to ask your doctor about your treatment and ABRAXANE®

ABRAXANE Patient Brochure (English Version)
ABRAXANE Patient Brochure (En Español)

This empowering resource will help you better understand metastatic breast cancer, ABRAXANE, and how to manage side effects that may occur. Important Web sites and books to assist patients during chemotherapy treatment are also listed.

ABRAXANE Patient Brochure

ABRAXANE Solvent Education Brochure
Get the basics on paclitaxel, the role of chemical solvents in drug delivery, premedication and associated risks, and what makes ABRAXANE a unique treatment option.

ABRAXANE Solvent Education Brochure

Full Prescribing Information
Complete Prescribing Information for ABRAXANE which includes a Patient Information Leaflet

 

Download Adobe Reader

To view this download, you need Adobe® Acrobat® Reader® installed. If you do not have Adobe Acrobat Reader on your computer, you can download it here.

Adobe Acrobat Reader is a registered trademark of Adobe Systems Incorporated.

 

 

 

WARNING: ABRAXANE for Injectable Suspension (paclitaxel protein-bound particles for injectable suspension) (albumin-bound) should be given under the care of a doctor experienced with cancer therapy in a health care facility that is capable of managing possible complications.

ABRAXANE should not be given to patients who have dangerously low white blood counts because of the risk for serious infections. Frequent blood tests are used to check white blood cell count during therapy with ABRAXANE.

An albumin form of paclitaxel may behave differently in the body than other paclitaxel medications. ABRAXANE SHOULD NOT BE SUBSTITUTED FOR OR WITH OTHER PACLITAXEL FORMULATIONS.

IMPORTANT SAFETY INFORMATION

One of the more important side effects associated with chemotherapy is a decrease in the number of infectionfighting white blood cells (neutrophils) called "neutropenia". ABRAXANE should not be given to patients with dangerously low white blood cell counts because of the risk for serious infections. Your doctor will schedule blood tests to check your white blood cell count (absolute neutrophil count [ANC]) during therapy with ABRAXANE. Tell your doctor if you have a fever or notice any other signs of an infection.

Women should avoid becoming pregnant while being treated with ABRAXANE. Tell your doctor if you are pregnant, if you become pregnant, or you plan to become pregnant while taking ABRAXANE. Nursing a baby while taking ABRAXANE is not recommended because the drug may be present in breast milk. Men should be advised not to father a child while receiving ABRAXANE.

ABRAXANE contains albumin a derivative of human blood.

The most important side effects have included hair loss, infections due to low white blood cell count, numbness, tingling or burning in the hands or feet, fatigue and weakness, low red blood cell count, mouth or lip sores, joint and muscle pain, stomach upset and diarrhea, heart and blood vessel (cardiovascular) effects and irritation at the injection site.

Numbness, tingling, or burning in the hands and feet (neuropathy) occurs with ABRAXANE and other paclitaxel medications. Be sure to tell your doctor if you experience these symptoms. Your doctor may interrupt treatment and restart at a lower dose after symptoms improve.

Other side effects have included blurred vision or eye irritation, fluid retention, liver and kidney dysfunction, low platelet counts, dehydration, fever and allergic reactions (which in rare cases were severe). Tell your doctor about any side effects that bother you.

Your ability to drive and use machines may be limited by side effects such as: fatigue, lethargy and malaise.

You are encouraged to report negative side effects of prescription drugs to the FDA. Visit www.FDA.gov/medwatch or call 1-800-FDA-1088.

The information on this site is intended for US residents only.

ABRAXANE is a registered
trademark of Abraxis BioScience, LLC.

All Abraxis BioScience, LLC.
corporate names, names of services,
and names of products referred to herein
are trade names, service marks, and/or
trademarks that are owned by or licensed
to Abraxis BioScience, its divisions or its
affiliates, unless otherwise noted.

©2010 Abraxis BioScience, LLC.
All Rights Reserved. AB 1650 05/10

Abraxis

WARNING: ABRAXANE for Injectable Suspension (paclitaxel protein-bound particles for injectable suspension) (albumin-bound) should be given under the care of a doctor experienced with cancer therapy in a health care facility that is capable of managing possible complications.

ABRAXANE should not be given to patients who have dangerously low white blood counts because of the risk for serious infections. Frequent blood tests are used to check white blood cell count during therapy with ABRAXANE.

An albumin form of paclitaxel may behave differently in the body than other paclitaxel medications. ABRAXANE SHOULD NOT BE SUBSTITUTED FOR OR WITH OTHER PACLITAXEL FORMULATIONS.

IMPORTANT SAFETY INFORMATION

One of the more important side effects associated with chemotherapy is a decrease in the number of infectionfighting white blood cells (neutrophils) called "neutropenia". ABRAXANE should not be given to patients with dangerously low white blood cell counts because of the risk for serious infections. Your doctor will schedule blood tests to check your white blood cell count (absolute neutrophil count [ANC]) during therapy with ABRAXANE. Tell your doctor if you have a fever or notice any other signs of an infection.

Women should avoid becoming pregnant while being treated with ABRAXANE. Tell your doctor if you are pregnant, if you become pregnant, or you plan to become pregnant while taking ABRAXANE. Nursing a baby while taking ABRAXANE is not recommended because the drug may be present in breast milk. Men should be advised not to father a child while receiving ABRAXANE.

ABRAXANE contains albumin a derivative of human blood.

The most important side effects have included hair loss, infections due to low white blood cell count, numbness, tingling or burning in the hands or feet, fatigue and weakness, low red blood cell count, mouth or lip sores, joint and muscle pain, stomach upset and diarrhea, heart and blood vessel (cardiovascular) effects and irritation at the injection site.

Numbness, tingling, or burning in the hands and feet (neuropathy) occurs with ABRAXANE and other paclitaxel medications. Be sure to tell your doctor if you experience these symptoms. Your doctor may interrupt treatment and restart at a lower dose after symptoms improve.

Other side effects have included blurred vision or eye irritation, fluid retention, liver and kidney dysfunction, low platelet counts, dehydration, fever and allergic reactions (which in rare cases were severe). Tell your doctor about any side effects that bother you.

Your ability to drive and use machines may be limited by side effects such as: fatigue, lethargy and malaise.

You are encouraged to report negative side effects of prescription drugs to the FDA. Visit www.FDA.gov/medwatch or call 1-800-FDA-1088.

The information on this site is intended for US residents only.

ABRAXANE is a registered trademark of Abraxis BioScience, LLC. Abraxis Oncology® is a division of Abraxis BioScience, LLC.

All Abraxis BioScience, LLC. corporate names, names of services, and names of products referred to herein are trade names, service marks, and/or trademarks that are owned by or licensed to Abraxis BioScience, its divisions or its affiliates, unless otherwise noted.

©2010 Abraxis BioScience, LLC.
All Rights Reserved. AB 1650   05/10
(Site updated 01/09)

Abraxis